Alba Llop-Guevara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alba Llop-Guevara has a total of 449 co-authors. Here are the top co-authors by number of shared publications:
- Violeta Serra
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
229 shared publications - Andrea Herencia-Ropero
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
120 shared publications - Benedetta Pellegrino
Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy
98 shared publications - Paolo Nuciforo
Molecular Oncology Group, Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain
72 shared publications - Amanda J. Compadre
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, MO; Divsion of Clinical Research, Department of Obstetrics and Gynecology, Washington University, St. Louis, MO
64 shared publications - Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri
64 shared publications
Latest Publications
- Open Access
- 11 July 2026
- Published by Springer Nature in npj Precision Oncology
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
PARP inhibitors (PARPi) are effective in tumors with homologous recombination repair (HRR) deficiency (HRD), typically identified by germline/tumor mutations. However, genetic testing may miss intrinsic PARPi sensitivity and resistance. We evaluated strategies to improve detection and longitudinal monitoring of HRD across >500 tumor samples and >20 paired liquid biopsies, integrating genetic, genomic, and functional readouts. HRD was more frequent in high-grade ovarian cancer (HGOC; 52%) than in metastatic breast (mBC; 12%) or prostate cancer (mPC; 20%). Assay concordance was low-to-moderate, underscoring complementarity. RAD51 testing and the genomic instability score identified HRD in tumors lacking pathogenic HRR mutations (6% and 30% in mBC, 38% and 46% in HGOC, 14% and 27% in mPC, respectively). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in >30% of post-PARPi mBC samples, which were associated with poor response to subsequent platinum therapy. These findings support the use of complementary HRD biomarkers in tissue and liquid biopsy to guide PARPi use and monitor response.
- 11 July 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessComprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
PARP inhibitors (PARPi) are effective in tumors with homologous recombination repair (HRR) deficiency (HRD), typically identified by germline/tumor mutations. However, genetic testing may miss intrinsic PARPi sensitivity and resistance. We evaluated strategies to improve detection and longitudinal monitoring of HRD across >500 tumor samples and >20 paired liquid biopsies, integrating genetic, genomic, and functional readouts. HRD was more frequent in high-grade ovarian cancer (HGOC; 52%) than in metastatic breast (mBC; 12%) or prostate cancer (mPC; 20%). Assay concordance was low-to-moderate, underscoring complementarity. RAD51 testing and the genomic instability score identified HRD in tumors lacking pathogenic HRR mutations (6% and 30% in mBC, 38% and 46% in HGOC, 14% and 27% in mPC, respectively). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in >30% of post-PARPi mBC samples, which were associated with poor response to subsequent platinum therapy. These findings support the use of complementary HRD biomarkers in tissue and liquid biopsy to guide PARPi use and monitor response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains